Trendlines Group

SINGAPORE (June 28): NRA Capital is reiterating its “overweight” recommendation on Trendlines Group with a fair value estimate of 22.5 cents.

SINGAPORE (June 19): Trendlines Group announced that its portfolio company, Arcuro Medical, has received regulatory clearance from the United States Food and Drug Administration (FDA) for its SuperBall meniscus repair system.

SINGAPORE (Feb 26): Trendlines announced that its portfolio company Saturas has completed an investment round of US$4 million ($5.27 million).

SINGAPORE (Feb 8): Trendlines Medical Singapore, a subsidiary of Israeli company The Trendlines Group, is partnering Singapore-based investor Ozi Amanat’s venture capital firm, K2 Global, to collaborate in SPRING SEEDS Capital’s (SSC) $100 million inv

SINGAPORE (Dec 8): The Trendlines Group’s announcement at end-October that it will start paying dividends in the next financial year could boost returns for long-suffering shareholders of the medical technology incubator.

SINGAPORE (Oct 16): Trendlines Medical Singapore, a 76.43%-owned subsidiary of Catalist-listed Israeli company The Trendlines Group, has made its first investment by committing a total of US$60,000 ($81,150) to a medical device start-up, InterVaal.

SINGAPORE (Oct 10): Trendlines Group, the investor, incubator and developer of early-stage medical and agricultural startup in Israel is raising net proceeds of $13.34 million by placing out 100 million new shares at 14.03 cents each.

SINGAPORE (Aug 30): A subsidiary of Trendlines Group is disposing its entire 6% stake in MitrAssist Medical for a consideration of US$1.15 million ($1.55 million).

SINGAPORE (June 27): Trendlines Group, the Catalist-listed innovation commercialisation company based in Israel, has announced that its Bayer Trendlines Ag Innovation Fund will be establishing a new company, ABI-Ag, to conduct specific research in the fie

SINGAPORE (June 6): Trendlines Group, the investor, incubator and developer of early-stage, high-promise medical and agricultural technology companies, has signed an agreement for the sale of BioSight to Arkin Bio Ventures.